Markets
Minerva Neurosciences, Inc. (NERV)
NERVNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$2.49
-0.1500 (-5.68%) today
At the close, Nov 10, 4:00 PM ET. After hours $2.49 –
-5.68% 1D
- Market cap
- $124.09m
- P/E
- –
- EPS, last 4 quarters
- $-2.87
- Dividend yield
- –
- Day range
- $2.38 to $2.67
- 52-week range
- $1.96 to $8.80
- Average volume
- 166.7k
- Previous close
- $2.64
Analysts
2 coveringBuy1 buy, 1 hold, 0 sell
Targets a year out average $8.50, +241.4% from here
$7.00now $2.49$10.00
Earnings
next estimate $-0.0900Next report
Dec 2025
-481.8%
Mar 2026
-30.8%
Jun 2026
–
Sep 2026
-1042.9%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$2.84m | -$4.98m | -$16.67m | -$10.64m |
| Net income | -$2.74m | -$283.67m | -$125.40m | $17.47m |
News
8 latest- Minerva Neurosciences, Inc. Reports Third Quarter 2026 Financial Results and Roluperidone Phase 3 Trial ProgressFintel · 4 days ago
- All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to BuyZacks · May 20, 2026
- Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks · May 20, 2026
- Minerva Neurosciences (NERV) Price Target Increased by 31.03% to 9.69Fintel · Apr 27, 2026
- Citizens Initiates Coverage of Minerva Neurosciences (NERV) with Market Outperform RecommendationFintel · Apr 15, 2026
- Minerva Neurosciences (NERV) Price Target Increased by 61.11% to 7.40Fintel · Mar 26, 2026
- Minerva Neurosciences (NERV) Price Target Increased by 12.50% to 4.59Fintel · Dec 6, 2025
- HC Wainwright & Co. Maintains Minerva Neurosciences (NERV) Neutral RecommendationFintel · Nov 6, 2025
The company
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is conducting a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- minervaneurosciences.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.